Pub Date : 2021-01-01DOI: 10.35248/2376-0389.21.8.264
Mark Vonnegut
To decide if treatment adequacy on backslides do empower to anticipate treatment viability on handicap deteriorating in numerous sclerosis patients and regardless of whether that viability is reliant upon age. The applicable provisions of distributed randomized controlled clinical preliminaries in MS were extricated by characterized models to be specific information on age pattern data backslides and extent of advancing patients. Relapse examinations were performed to investigate the connection between treatment viability on backslides and on affirmed incapacity movement over preliminaries span just as among age and those clinical results. 53 preliminaries involving 76 examination arms and aggregating 34.765 patients were chosen and occupied with the resulting investigations. Critical relationship was seen between the treatment impact on backslides and on affirmed inability movement (changed R2 =0.3872). A solid affiliation was found between the pattern EDSS and benchmark age (changed R2 =0.6243) and a critical affiliation was enrolled between the treatment impact on affirmed incapacity movement and age (changed R2 =0.3179).
{"title":"Measurably Relating Treatment Effects on Disintegration and Impairmentnoun in Multiple Sclerosis Patients","authors":"Mark Vonnegut","doi":"10.35248/2376-0389.21.8.264","DOIUrl":"https://doi.org/10.35248/2376-0389.21.8.264","url":null,"abstract":"To decide if treatment adequacy on backslides do empower to anticipate treatment viability on handicap deteriorating in numerous sclerosis patients and regardless of whether that viability is reliant upon age. The applicable provisions of distributed randomized controlled clinical preliminaries in MS were extricated by characterized models to be specific information on age pattern data backslides and extent of advancing patients. Relapse examinations were performed to investigate the connection between treatment viability on backslides and on affirmed incapacity movement over preliminaries span just as among age and those clinical results. 53 preliminaries involving 76 examination arms and aggregating 34.765 patients were chosen and occupied with the resulting investigations. Critical relationship was seen between the treatment impact on backslides and on affirmed inability movement (changed R2 =0.3872). A solid affiliation was found between the pattern EDSS and benchmark age (changed R2 =0.6243) and a critical affiliation was enrolled between the treatment impact on affirmed incapacity movement and age (changed R2 =0.3179).","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"124 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81737738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2376-0389.21.8.244
Evelyn Joy
Tuberous sclerosis complex (TSC) is a genetic disorder that is manifested in multiple body systems. Diabetes mellitus is a disorder of carbohydrate metabolism characterized by impaired ability of the body to produce or respond to insulin and thereby maintain proper levels of glucose in the blood. mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases (PIKKs)
{"title":"Diabetes in Individuals with Tuberous Sclerosis Complex Treated with MTOR Inhibitors","authors":"Evelyn Joy","doi":"10.35248/2376-0389.21.8.244","DOIUrl":"https://doi.org/10.35248/2376-0389.21.8.244","url":null,"abstract":"Tuberous sclerosis complex (TSC) is a genetic disorder that is manifested in multiple body systems. Diabetes mellitus is a disorder of carbohydrate metabolism characterized by impaired ability of the body to produce or respond to insulin and thereby maintain proper levels of glucose in the blood. mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases (PIKKs)","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"34 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87626986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2376-0389.21.8.233
Gowthami Bainaboina
Alcoholic Neuropathy could be a severe condition caused by excessive alcohol use harm to the nerves ends up in reduced quality, uncommon sensations within the limbs, and loss of some bodily functions. If we tend to recognise symptoms early, it should scale back the severity
{"title":"A Brief Note on Alcoholic Neuropathy","authors":"Gowthami Bainaboina","doi":"10.35248/2376-0389.21.8.233","DOIUrl":"https://doi.org/10.35248/2376-0389.21.8.233","url":null,"abstract":"Alcoholic Neuropathy could be a severe condition caused by excessive alcohol use harm to the nerves ends up in reduced quality, uncommon sensations within the limbs, and loss of some bodily functions. If we tend to recognise symptoms early, it should scale back the severity","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"282 1 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86578525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2376-0389.21.8.E101
Evelyn Joy
Welcome to the page, whether you are a new reader or returning reader, we are exiting to have you with us for a promising peer-reviewing, open access journal and is one of the leading Journal in the field of Multiple Sclerosis Journals as per Google ranking. The Journal aims to publish articles on the topic of Multiple Sclerosis under Neuroscience area and its applied fields.
{"title":"The Compendium of Journal of Multiple Sclerosis","authors":"Evelyn Joy","doi":"10.35248/2376-0389.21.8.E101","DOIUrl":"https://doi.org/10.35248/2376-0389.21.8.E101","url":null,"abstract":"Welcome to the page, whether you are a new reader or returning reader, we are exiting to have you with us for a promising peer-reviewing, open access journal and is one of the leading Journal in the field of Multiple Sclerosis Journals as per Google ranking. The Journal aims to publish articles on the topic of Multiple Sclerosis under Neuroscience area and its applied fields.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"19 1","pages":"1-2"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77538437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2376-0389.21.8.256
Emma Rollas
The assessment of older folks has to cowl the psychological domain of health, with attention on the individual’s behavior and mind. The most health issues poignant older folks during this domain are psychological feature impairment, depression and delirium. Though these are completely different health problems, their symptoms overlap and will gift at the same time this complicates diagnosing and therefore the alternative of treatment. Careful assessment is vital to succeed in the proper diagnosing, give applicable treatment and perceive the patient’s care desires. Over 2 hundredth of adults aged sixty and over suffer from a mental or disorder (excluding headache disorders) and half dozen.6% of all incapacity (disability adjusted life yearsDALYs) among folks over sixty years is attributed to mental and medicine disorders.
{"title":"A Short Note on the Assessment and Treatment of Behavioral and Psychological Health in Older patients","authors":"Emma Rollas","doi":"10.35248/2376-0389.21.8.256","DOIUrl":"https://doi.org/10.35248/2376-0389.21.8.256","url":null,"abstract":"The assessment of older folks has to cowl the psychological domain of health, with attention on the individual’s behavior and mind. The most health issues poignant older folks during this domain are psychological feature impairment, depression and delirium. Though these are completely different health problems, their symptoms overlap and will gift at the same time this complicates diagnosing and therefore the alternative of treatment. Careful assessment is vital to succeed in the proper diagnosing, give applicable treatment and perceive the patient’s care desires. Over 2 hundredth of adults aged sixty and over suffer from a mental or disorder (excluding headache disorders) and half dozen.6% of all incapacity (disability adjusted life yearsDALYs) among folks over sixty years is attributed to mental and medicine disorders.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"29 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85930369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-01DOI: 10.35248/2376-0389.21.8.249
B. Princy, La
{"title":"Chemokines in the Central Nervous System and Alzheimer's Disease","authors":"B. Princy, La","doi":"10.35248/2376-0389.21.8.249","DOIUrl":"https://doi.org/10.35248/2376-0389.21.8.249","url":null,"abstract":"","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"1 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82322882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In March 2020 the WHO declared that COVID-19 had reached pandemic state. To date the primary focus internationally has been on the preservation of life. For those with pre-existing neurological disease, there is an additional concern with early evidence suggesting this group could be predisposed to adverse outcomes. Multiple sclerosis (MS) patients are a particularly vulnerable group during this pandemic. The combination of an autoimmune neurodegenerative disorder and the immunosuppression caused by the typically prescribed pharmacological agents augments the risk of complications in this group [1]. As a public health precaution, international governmental bodies recommended that people with multiple sclerosis (pwMS) self-isolate as much as possible to reduce their risk of contracting the virus.
{"title":"Bridging the Gap in Multiple Sclerosis Rehabilitation During Covid-19","authors":"E. Synnott","doi":"10.4172/2376-0389.E102","DOIUrl":"https://doi.org/10.4172/2376-0389.E102","url":null,"abstract":"In March 2020 the WHO declared that COVID-19 had reached pandemic state. To date the primary focus internationally has been on the preservation of life. For those with pre-existing neurological disease, there is an additional concern with early evidence suggesting this group could be predisposed to adverse outcomes. Multiple sclerosis (MS) patients are a particularly vulnerable group during this pandemic. The combination of an autoimmune neurodegenerative disorder and the immunosuppression caused by the typically prescribed pharmacological agents augments the risk of complications in this group [1]. As a public health precaution, international governmental bodies recommended that people with multiple sclerosis (pwMS) self-isolate as much as possible to reduce their risk of contracting the virus.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"14 1","pages":"1-1"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87617264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.4172/2376-0389.1000226
D. Colombo, E. Zagni, Aless, ra Ori, N. Montano, G. D. Angelis, E. Vanoli
Objective: Fingolimod, a second-line therapy for relapsing-remitting multiple sclerosis, may cause transitory effects on heart rate and atrioventricular conduction that may result in bradycardia and atrioventricular blocks, mainly following first administration; an ECG monitoring for at least 6 hours is therefore recommended, to be extended in case of bradycardia. The BEAT study showed that the dominance of cardiac vagal modulation, though not representing a risk factor for rhythm complications, can help identifying patients with higher probability to require extended monitoring. Methods: This is a post-hoc analysis of the BEAT study, aimed at assessing the association between gender and need of extension of the ECG and gender differences in patients’ satisfaction with drug administration and monitoring experience. Results: Of the 625 patients evaluated in the BEAT study (67% were women), only 45 (7.2%; 95% CI: 5.3%; 9.5%) required an extended monitoring. Gender differences emerged in the assumption of drugs altering heart rate or atrioventricular conduction (6.4% of females vs. 0.5% of males, Chi-square test p-value=0.001) and in the sympathovagal balance status (median (interquartile range) RR LF/HF in women: 3.3 (1.3-7.4) respectively vs. 4.5 (2.1-10.2) in men, Wilcoxon test p-value=0.001). However, keeping constant the effect of these variables, no association emerged between sex and early ECG abnormalities requiring a prolongation of post-first dose monitoring. Our specifically developed satisfaction score showed a higher level of satisfaction with the overall care experience in women than in men (beta female vs. male=1.69 points) and women perceived a greater favorable impact of the drug on their daily living than man (median of ‘impact of treatment’ item in males and females 7.0 and 2.0, respectively, Wilcoxon test p-value=0.005). Conclusion: No association emerged between sex and early ECG response to fingolimod administration requiring extended cardiac monitoring. More women than men reported a higher level of satisfaction with drug administration and monitoring procedures.
{"title":"Is Gender Associated to Extended Cardiac Monitoring after First Dose of Fingolimod and Level of Satisfaction with the Monitoring Experience in Relapsing-Remitting Multiple Sclerosis Patients? A Post-hoc Analysis of the BEAT Study","authors":"D. Colombo, E. Zagni, Aless, ra Ori, N. Montano, G. D. Angelis, E. Vanoli","doi":"10.4172/2376-0389.1000226","DOIUrl":"https://doi.org/10.4172/2376-0389.1000226","url":null,"abstract":"Objective: Fingolimod, a second-line therapy for relapsing-remitting multiple sclerosis, may cause transitory effects on heart rate and atrioventricular conduction that may result in bradycardia and atrioventricular blocks, mainly following first administration; an ECG monitoring for at least 6 hours is therefore recommended, to be extended in case of bradycardia. The BEAT study showed that the dominance of cardiac vagal modulation, though not representing a risk factor for rhythm complications, can help identifying patients with higher probability to require extended monitoring. Methods: This is a post-hoc analysis of the BEAT study, aimed at assessing the association between gender and need of extension of the ECG and gender differences in patients’ satisfaction with drug administration and monitoring experience. Results: Of the 625 patients evaluated in the BEAT study (67% were women), only 45 (7.2%; 95% CI: 5.3%; 9.5%) required an extended monitoring. Gender differences emerged in the assumption of drugs altering heart rate or atrioventricular conduction (6.4% of females vs. 0.5% of males, Chi-square test p-value=0.001) and in the sympathovagal balance status (median (interquartile range) RR LF/HF in women: 3.3 (1.3-7.4) respectively vs. 4.5 (2.1-10.2) in men, Wilcoxon test p-value=0.001). However, keeping constant the effect of these variables, no association emerged between sex and early ECG abnormalities requiring a prolongation of post-first dose monitoring. Our specifically developed satisfaction score showed a higher level of satisfaction with the overall care experience in women than in men (beta female vs. male=1.69 points) and women perceived a greater favorable impact of the drug on their daily living than man (median of ‘impact of treatment’ item in males and females 7.0 and 2.0, respectively, Wilcoxon test p-value=0.005). Conclusion: No association emerged between sex and early ECG response to fingolimod administration requiring extended cardiac monitoring. More women than men reported a higher level of satisfaction with drug administration and monitoring procedures.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"80 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87632347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.4172/2376-0389.1000227
E. Synnott, K. Baker
Background: Balance related dysfunction remains a debilitating clinical manifestation among people with Multiple Sclerosis (pwMS) causing significant morbidity and reduced quality of life. Imbalance is found to stem primarily from neurophysiological causes. Current management strategies have shown to have small but clinically insignificant results with little consideration towards vestibular sources of postural instability. Vestibular rehabilitation (VR) provides a promising treatment strategy to mediate balance dysfunction among people with pwMS. Design: Systematic Review, guided by PRISMA guidelines and presenting a best evidence synthesis. Data sources: 10 electronic databases were searched from inception until September 2019. Eligibility criteria for study selection: Article of original research, population of patients with multiple sclerosis aged over 18, interventions detailing VR protocols, measurement of outcomes pre-VR/post-VR. Results: Seven articles satisfied the eligibility criteria. 6/7 studies were rated as high quality and regarded as level one evidence. 5 studies consisted of standardised VR protocols while 2 studies consisted of customised VR. All studies identified improvements of mixed significance in balance, fatigue and dizziness outcomes post VR. Heterogeneity among VR prescription patterns limited optimal prescription guidelines. Conclusions: The available evidence shows promise that VR is a safe and effective strategy to provide short term benefits in balance related dysfunction in pwMS. Recommendations of mixed strength are made based on the quality of current literature. Current evidence for optimal prescription and long-term effects of VR is limited. Further high-level studies evaluating the effects of VR in patients with multiple sclerosis with vestibular and/or balance dysfunction are required.
{"title":"The Effectiveness of Vestibular Rehabilitation on Balance Related Impairments among Multiple Sclerosis Patients: A Systematic Review","authors":"E. Synnott, K. Baker","doi":"10.4172/2376-0389.1000227","DOIUrl":"https://doi.org/10.4172/2376-0389.1000227","url":null,"abstract":"Background: Balance related dysfunction remains a debilitating clinical manifestation among people with Multiple Sclerosis (pwMS) causing significant morbidity and reduced quality of life. Imbalance is found to stem primarily from neurophysiological causes. Current management strategies have shown to have small but clinically insignificant results with little consideration towards vestibular sources of postural instability. Vestibular rehabilitation (VR) provides a promising treatment strategy to mediate balance dysfunction among people with pwMS. Design: Systematic Review, guided by PRISMA guidelines and presenting a best evidence synthesis. Data sources: 10 electronic databases were searched from inception until September 2019. Eligibility criteria for study selection: Article of original research, population of patients with multiple sclerosis aged over 18, interventions detailing VR protocols, measurement of outcomes pre-VR/post-VR. Results: Seven articles satisfied the eligibility criteria. 6/7 studies were rated as high quality and regarded as level one evidence. 5 studies consisted of standardised VR protocols while 2 studies consisted of customised VR. All studies identified improvements of mixed significance in balance, fatigue and dizziness outcomes post VR. Heterogeneity among VR prescription patterns limited optimal prescription guidelines. Conclusions: The available evidence shows promise that VR is a safe and effective strategy to provide short term benefits in balance related dysfunction in pwMS. Recommendations of mixed strength are made based on the quality of current literature. Current evidence for optimal prescription and long-term effects of VR is limited. Further high-level studies evaluating the effects of VR in patients with multiple sclerosis with vestibular and/or balance dysfunction are required.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"21 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91005585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-01-01DOI: 10.4172/2376-0389.1000229
C. Kutz
Background: Alemtuzumab treatment of patients with MS is associated with cytokine release, resulting in infusion-associated reactions (IARs). Premedication with corticosteroids is typically administered to alleviate the risk of IARs, but steroid pretreatment is not feasible in some patients. This study investigated real-world experience using repository corticotropin injection (RCI) as a pretreatment for alemtuzumab infusion. Methods: A retrospective study of patients who were prescribed RCI as pretreatment for the prevention of alemtuzumab IARs was conducted using an electronic questionnaire. Data were de-identified at the time of collection. Results: Complete information on 175 patients was collected and analyzed. Data for alemtuzumab Course 1 infusions were available for 175 patients; 23 of these also had data available for Course 2 infusions. Patients were 62% Caucasian, 21% black, 15% Hispanic, and were diagnosed with relapsing forms of MS (60%) or progressive forms of MS (40%). Reasons for using RCI prior to alemtuzumab included history of steroid intolerance (Course 1: 37%, Course 2: 59%), history of poor response to steroids (20%, 27%), and comorbidities (20%, 27%). RCI was most frequently administered subcutaneously at a dose of 80 units. No IARs occurred in 56% (Course 1) and 61% (Course 2) of patients after RCI pretreatment. No adverse events attributed to RCI were seen in 72% and 91% of patients treated with Course 1 and 2, respectively. Conclusion: RCI is a safe, effective, and well-tolerated pretreatment alternative to corticosteroids to alleviate the risk of alemtuzumab-associated infusion reaction in patients with MS.
{"title":"A Retrospective Study of Utilization of Repository Corticotropin Injection (HP Acthar Gel) as Pretreatment for Alemtuzumab Infusion","authors":"C. Kutz","doi":"10.4172/2376-0389.1000229","DOIUrl":"https://doi.org/10.4172/2376-0389.1000229","url":null,"abstract":"Background: Alemtuzumab treatment of patients with MS is associated with cytokine release, resulting in infusion-associated reactions (IARs). Premedication with corticosteroids is typically administered to alleviate the risk of IARs, but steroid pretreatment is not feasible in some patients. This study investigated real-world experience using repository corticotropin injection (RCI) as a pretreatment for alemtuzumab infusion. Methods: A retrospective study of patients who were prescribed RCI as pretreatment for the prevention of alemtuzumab IARs was conducted using an electronic questionnaire. Data were de-identified at the time of collection. Results: Complete information on 175 patients was collected and analyzed. Data for alemtuzumab Course 1 infusions were available for 175 patients; 23 of these also had data available for Course 2 infusions. Patients were 62% Caucasian, 21% black, 15% Hispanic, and were diagnosed with relapsing forms of MS (60%) or progressive forms of MS (40%). Reasons for using RCI prior to alemtuzumab included history of steroid intolerance (Course 1: 37%, Course 2: 59%), history of poor response to steroids (20%, 27%), and comorbidities (20%, 27%). RCI was most frequently administered subcutaneously at a dose of 80 units. No IARs occurred in 56% (Course 1) and 61% (Course 2) of patients after RCI pretreatment. No adverse events attributed to RCI were seen in 72% and 91% of patients treated with Course 1 and 2, respectively. Conclusion: RCI is a safe, effective, and well-tolerated pretreatment alternative to corticosteroids to alleviate the risk of alemtuzumab-associated infusion reaction in patients with MS.","PeriodicalId":16369,"journal":{"name":"Journal of multiple sclerosis","volume":"27 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82821108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：